In a longer and larger observational study of German patients, followed up for 1–31 years, mortality was 43% among the seven untreated homozygotes compared with 21% in the 14 who were treated with Lp ...

Apo B tests are blood tests that measure the concentration of Apolipoprotein B in the blood, which carries cholesterol that ...

HDL was reduced from 1.0 ± 0.2 mmol/L pre- to 0.5 ± 0.1 mmol/L post-apheresis (p = 0.03). It increased following apheresis and then remained constant throughout the evolocumab treatment. Lp(a) ...

Subhash Banerjee, MD (VA North Texas Health Care System & UT Southwestern Medical Center, Dallas), who presented the results of the PREMIER trial in a featured clinical research session at the annual ...

Please provide your email address to receive an email when new articles are posted on . LAS VEGAS — LDL apheresis was safe and was linked to a trend toward early coronary atheroma regression in ...

Evinacumab (Regeneron), a fully human monoclonal antibody inhibitor of angiopoietin-like protein 3 (ANGPTL3), substantially lowers LDL cholesterol in patients with homozygous familial ...

B. Braun Medical’s renal therapies division has announced the availability of the Plasmat Futura System for heparin-induced extracorporeal lipoprotein precipitation (HELP) LDL Apheresis therapy. HELP ...

Dennis R. Leahy, MD, shares his POV on the value of making Lp(a) testing universal, not only to inform patients and their clinicians of the high CV risks, but to make way for potential treatments.

SAN DIEGO, CA. - September 11, 2025 (NEWMEDIAWIRE) - Sigyn Therapeutics, Inc. ("Sigyn" or the "Company") (OTCQB: SIGY), a developer of dialysis-like therapies to address cardiovascular disease and ...

An acute reduction in total cholesterol of ≥65%, or in LDL cholesterol of ≥70%, during each procedure; An interval mean total cholesterol of <7 mmol/l or LDL cholesterol <6.5 mmol/l (or decreases of ...